Preclinical data highlighted ability of HotSpot’s CBL-B inhibitors to enhance the effector function and proliferation of natural killer cells, which...
Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of HST-1011 dosed as...
BOSTON, Mass., Mar. 14, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
BOSTON, Mass., January 03, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
NORTH CHICAGO, Ill. and BOSTON, Mass., December 06, 2022 – AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company...
BOSTON, Mass., November 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of orally delivered,...
BOSTON, Mass., October 5, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
BOSTON, Mass., July 25, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...
BOSTON, Mass., July 19, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...
BOSTON, Mass., Apr. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
BOSTON, Mass., Mar. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
BOSTON, Mass., Feb. 17, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
BOSTON, Mass., Jan. 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
Boston, Mass., Nov 29, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Boston, Mass., Nov. 16, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering thediscovery and development of first-in-class allosteric therapies...
Boston, Mass., Nov. 9, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...
BOSTON, Mass. (Oct. 11, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
BOSTON, Mass. (April 14, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
BOSTON, Mass. (November 17, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
BOSTON, Mass. (May 21, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
BOSTON, Mass. (August 23, 2019)— HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...
CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...
“HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us...
AbbVie has formed a connection with HotSpot Therapeutics, inking a global licensing option deal for the biotech’s preclinical small-molecule allosteric therapy and extending the opportunity for up to $295 million in biobucks.
HotSpot Therapeutics has managed to gain some steam financially in the past few years, as the company wrangled several multi-million dollar raises. But its latest deal not only puts more cash into its pockets, it also connects with a major name in pharma.
In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge.
DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output.
HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies.
HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites.
Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them.
After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets
HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T
HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.
In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.
Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni
HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.
With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.
